CellaVision

Sales recovery with all-time high in Americas

Källa: MFN
Negativ

Sammanfattning

CellaVision redovisar en omsättningsökning på 4,5% till 200 MSEK för andra kvartalet 2026, med organisk tillväxt på 5,6%. EBITDA minskade till 55 MSEK (60 MSEK) på grund av engångskostnader relaterade till VD-byte, men justerat för detta ökade EBITDA. Vinst per aktie minskade till 1,37 SEK (1,58 SEK).

Analys

Bolaget visar en viss omsättningsåterhämtning med positiv organisk tillväxt, men marginalerna pressas av engångskostnader för VD-övergången. Även om den justerade EBITDA-marginalen förbättrades, är det rapporterade resultatet och kassaflödet svagare än föregående år. Utnämningen av en ny VD och ny styrelseordförande är betydande händelser som kan påverka bolagets framtida strategi.

Nyckeltal

Net sales
200 m (191)
Organic sales growth
5.6% (7.6)
EBITDA
55 m (60)
EBITDA margin
27% (31)
Earnings per share
1.37 (1.58)
Cash flow from operating activities
29 m (58)

Insikter

  • • Engångskostnader för VD-byte påverkade resultatet negativt under kvartalet.
  • • Nya ledningspositioner (VD och styrelseordförande) kan signalera strategiska förändringar.
  • • Trots svagare rapporterade siffror, indikerar justerade siffror en underliggande operativ förbättring.

Organic sales growth:Q2, 2026: 5.6% (7.6)

EBITDA margin:*Q2, 2026: 27% (31)

April 1 – June 30, 2026Net sales increased by 4.5% (1.9) to SEK 200 m (191).Sales increased organically by 5.6% (7.6), currency effect -1.1% (-5.8).EBITDA amounted to SEK 55 m (60).*EBITDA margin amounted to 27% (31).*Profit before tax amounted to SEK 41 m (48).Earnings per share before and after dilution amounted to SEK 1.37 (1.58).Cash flow from operating activities amounted to SEK 29 m (58).

Significant events during the periodSteve Ferguson has been appointed Chief Executive Officer (CEO) as of June 5, 2026.At the Annual General Meeting April 28, 2026, Zlatko Rihter was elected as the new Chairmanof the Board of Directors and Louise Armstrong-Denby resigned as Board member.

* EBITDA for the second quarter 2026 was charged with expenses of SEK 9 m associated with the initial phase of the CEO transition. Adjusted for this, EBITDA and the EBITDA margin increased compared with the same quarter last year.

Contact

Lisa Bodily NordqvistInvestor Relations and Corporate Communications ManagerPhone: + 46 76 345 31 87E-mail: lisa.bodilynordqvist@cellavision.comwww.cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company’s 13 local market support organizations covering more than 40 countries. In 2025, sales were SEK 759 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-07-17 07:20 CEST.

Attachments

Interim Report Q2 2026

Öppna PDF

Fler nyheter från CellaVision

Relaterade pressmeddelanden och bolagshändelser från samma bolag.

Se bolagssidan
CellaVision: Sales recovery with all-time high in Americas - pressmeddelande och analys | Tickr